D(3) DOPAMINE RECEPTOR

Approval Year

Substance Class	Protein Created by `admin` on `Sat Jun 26 16:52:05 UTC 2021` Edited by `admin` on `Sat Jun 26 16:52:05 UTC 2021`
Protein Type	RECEPTOR
Protein Sub Type
Sequence Origin	HUMAN
Sequence Type	COMPLETE
Record UNII	G9XQ9S7T2F
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

D(3) DOPAMINE RECEPTOR

Common Name

English

DOPAMINE D3 RECEPTOR

Common Name

English

Code System Code Type Description

FDA UNII

G9XQ9S7T2F

Created by admin on Sat Jun 26 16:52:07 UTC 2021 , Edited by admin on Sat Jun 26 16:52:07 UTC 2021

PRIMARY

From	To
1_103	1_181
1_355	1_358

Glycosylation Type

HUMAN

Glycosylation Link Type	Site
N	1_12
N	1_19
N	1_97
N	1_173

Related Record Type Details


					87T4T8BO2E

ROTIGOTINE

AGONIST -> TARGET


					838F01T721

PALIPERIDONE

INHIBITOR -> TARGET

Interaction Type:

INHIBITOR

Qualification:

Ki

Amount:


					F6RJL8B278

CARIPRAZINE

PARTIAL AGONIST->TARGET

Comments:

Most of the clinically used antipsychotics display fairly high affinity for D3 receptors in vitro, they lack significant D3 receptor binding in vivo. They also do not occupy D3 receptors in schizophrenic patients at clinically-relevant doses, despite having significant and expected D2 receptor occupancy. The lack of in vivo D3 receptor occupancy of currently used antipsychotics may be due to their inability to displace endogenous DA from these sites; especially since DA has approximately 20- fold higher affinity for D3 vs D2 receptors and D3 (but not D2) receptors exist predominantly in a high affinity state for DA”

Qualification:

Ki

Amount: